Mizuho Maintains Buy on Quest Diagnostics, Raises Price Target to $155
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Ann Hynes maintains a Buy rating on Quest Diagnostics (NYSE:DGX) and increases the price target from $150 to $155.
April 24, 2024 | 11:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Ann Hynes reaffirms a Buy rating on Quest Diagnostics and raises the price target to $155.
The upgrade in the price target by a reputable analyst like Ann Hynes from Mizuho is a strong positive signal for Quest Diagnostics. It suggests a bullish outlook on the stock's future performance, potentially leading to increased investor confidence and a rise in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100